Hims & Hers Health shares rallied in afternoon trading after an FDA advisory panel recommended adding the peptide BPC-157 to the Section 503A Bulks List, a change that would create a legal pathway for prescription compounding of the product. The Pharmacy Compounding Advisory Committee voted 8-6 in favor, with one member abstaining, producing a stronger-than-expected regulatory outcome for the company.
The committee's decision was notable because FDA staff had earlier expressed skepticism about BPC-157, citing limited human data and outstanding safety concerns. That prior caution had left investors braced for a negative ruling, so the narrow favorable vote represented a meaningful surprise and a catalyst for the stock.
Market reaction was concentrated on the company itself rather than driven by broader equity markets. Hims & Hers rallied roughly 4.9% in afternoon trading even as major indexes fell: the S&P 500 slid 1.4%, the Dow Jones fell 1.1%, and the Nasdaq dropped 2.3%. The stock moved from an intraday low of $30.81 to a session high of $35.85 before settling into afternoon trade.
Investors are framing the vote as strategically important for Hims & Hers because the company has been positioning itself within the peptide category. The firm completed an acquisition of a California-based peptide manufacturing facility in early 2025, an asset that aligns with the potential market that could emerge if BPC-157 is reclassified for compounding.
It is important to emphasize that the advisory committee's recommendation is non-binding. The FDA retains final decision-making authority over whether to add BPC-157 to the Section 503A Bulks List. Market participants are treating the advisory panel's narrow approval as a step forward rather than a definitive regulatory victory.
Additional advisory votes are scheduled on other peptides today, including KPV, TB-500, and MOTS-c, with three more compounds set for review on Friday. Those upcoming reviews create a stream of potential near-term catalysts that market participants are watching closely.
Sentiment going into the committee meeting was cautious. The stock had declined for three straight sessions ahead of the vote, and that weakness was in part attributed to a recent sale of roughly $229,000 in shares by the company's chief financial officer just prior to the FDA event. That pre-event positioning left the share price more depressed than might otherwise have been the case, amplifying the rebound when the committee vote surprised to the upside.
Taken together, the unexpectedly favorable advisory outcome, Hims & Hers' prior investment in peptide manufacturing capacity, and the deeply discounted pre-event market positioning combined to produce today's sharp recovery in the stock's price. While the committee's decision provided a near-term boost, the ultimate regulatory status and further votes on related peptides remain key variables for the company's outlook.